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Objective: The aim of the study was to formulate and evaluate mucoadhesive buccal tablets of carvedilol to avoid the first-pass metabolism. 
Methods: Mucoadhesive Buccal tablets of carvedilol were prepared by direct compression techniques using a combination of bioadhesive polymers 
such as hydroxypropyl cellulose (HPC) and polyethlyelne oxide WSR-1105 (PEO WSR-1105). In order to improve solubility of carvedilol, solid 
dispersion was prepared using poloxamer 188. A 32 Full factorial design was applied to investigate the combined effect of the two independent 
variables i.e. concentration of HPC (X1) and concentration of PEO WSR-1105(X2) on the dependent variables, % in vitro drug release at 1 h (Y1), % 
in vitro drug release at 4 h (Y2), mucoadhesive strength (Y3) and mucoadhesion time (Y4
Results: Optimized mucoadhesive buccal tablets shows in vitro drug release of 96.23±2.45 in 8 h, mucoadhesive strength of 18.20±1.44 g, mucoadhesion 
time 420±2.6 min and surface pH 6.75±0.015. Drug excipients compatibility study by FTIR showed no interaction between drug and excipients. 
). 
Conclusion: From all parameters and experimental design evaluation, it was concluded that the drug release rate decreased with an increase the 
concentration of HPC and PEO WSR-1105 and mucoadhesion property increased with increase the concentration of PEO WSR-1105. The in vitro 
release kinetics revealed the Korsmeyer-Peppas model is followed and drug release is by anomalous diffusion. 
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© 2020 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/) 
DOI: http://dx.doi.org/10.22159/ijap.2020v12i4.37849. Journal homepage: https://innovareacademics.in/journals/index.php/ijap  
 
INTRODUCTION 
Bioadhesive buccal delivery of drugs is one of the alternatives to the 
oral route of drug administration, particularly to those drugs that 
undergo first pass metabolism [1, 2]. Problems accompanied with 
oral route of administration such as extensive metabolism by liver, 
drug degradation in the gastrointestinal tract due to harsh 
environment, and invasiveness of parenteral administration can be 
solved by administering the drug through the buccal route [1, 3, 4]. 
Buccal drug delivery systems offer a promising route for drug 
delivery not only to the buccal mucosa for the treatment of oral 
conditions but also for systemic delivery by absorption through the 
mucosa to the systemic circulation at a predetermined and 
controlled rate [5, 6]. In addition, the buccal mucosa permits 
prolonged retention of a dosage form, especially with the use of 
mucoadhesive polymers without much interference in activities such 
as speech or mastication unlike the sublingual route [5, 7]. Buccal 
drug delivery allows interruptions at any time in the case of toxicity 
or adverse effects. It is also possible to administrate drugs to 
patients who have difficulties in swallowing [8]. 
Carvedilol is a non-selective β-adrenergic antagonist used in the 
treatment of hypertension and stable angina pectoris. It also possesses 
antioxidant and antiproliferative effects, which may enhance its ability 
to combat the deleterious effects of sympathetic nervous system 
activation in heart failure [9, 10]. It is rapidly absorbed after an oral 
administration, the bioavailability of carvedilol is 25%–35% as it 
undergoes stereo-selective first-pass metabolism. Carvedilol is a weak 
base with pKa value 7.7–7.9 and log PC (partition coefficient) value of 
3.967, which indicates sufficient lipophilicity to pass through any 
biological membrane, including buccal membranes [5]. In the present 
study, mucoadhesive buccal tablets of carvedilol were developed using 
a combination of bioadhesive polymers such as hydroxypropyl 
cellulose (HPC) and polyethylene oxide WSR-1105 (PEO WSR-1105) to 
avoid first-pass metabolism. 
MATERIALS AND METHODS 
Materials 
Carvedilol was obtained a gift sample from Cadila Pharmaceutical 
Ltd, Dholka, Ahmedabad. Poloxamer 188, hydroxypropyl cellulose, 
polyethylene oxide WSR-1105, pearlitol 200 SD, magnesium 
stearate, aerosil and polyvinylpyrrolidone (PVP K-30) were 
purchased form Yarrow chem Product, Mumbai. Aspartame was 
procured from Forbes Pharmaceutical, Mumbai. 
Drug-excipient interaction study by FTIR 
FTIR study carried out to identify the drug sample and to establish 
drug-polymer compatibility in physical mixture of drug and polymers. 
Fourier Transform Infrared Spectroscopy carried out by diluting the 
sample with dried potassium bromide and acquiring IR spectrum in 
the range of 400-4000 cm-1
Preparation of solid dispersion by melting method 
. FTIR spectra of pure drug, and physcial 
mixture (drug+poloxamer 188+HPC+PEO) were taken [11]. 
Accurately weigh the drug and poloxamer 188. In this method, 
poloxamer 188 was melted to a temperature slightly above its 
melting point and the drug is incorporated into the matrix to ensure 
a homogenous dispersion of the drug in the matrix. The dispersion 
was cooled rapidly in an ice bath. The obtained dried mass is 
pulverized and sieved through # 40 [12-14]. 
Characterization of solid dispersion by differential scanning 
calorimetry (DSC) study 
Differential Scanning Calorimetry (DSC) spectra of (i) carvedilol (ii) 
poloxamer 188 (iii) drug+poloxamer 188 physical mixture (iv) solid 
dispersion of all these were recorded using DSC instrument of the 
institute (DSC-60, Shimadzu Corporation, Japan). The samples were 
heated in sealed aluminum pans under airflow (30 ml/min) at a 
scanning rate of 10 °C/min from 30 to 300 °C. Empty aluminum pan 
was used as a reference. The heat flow as a function of temperature 
was measured for the samples [15]. 
Preparation of buccal tablet 
Carvedilol buccal tablets were prepared by direct compression 
techniques. All ingredients and carvedilol solid dispersion were 
accurately weighed. All ingredients and carvedilol solid dispersion 
was passed through sieve # 40 and mixed thoroughly for 10 min. 
The blend was lubricated with aerosil and magnesium stearate for 2 
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min. The lubricated blend was compressed using 8 mm punch in 
single rotary tablet compression machine (Karnavati Engineering, 
Mehsana) [11, 16]. 
Experimental design 
In this design, two factors were evaluated each at three levels and 
experimental trials was performed using all possible nine 
combination. In this present study, concentration of HPC (X1) and 
concentration of PEO WSR-1105 (X2) were selected as independent 
variables. The % in vitro drug release at 1 h, (Y1), in vitro drug 
release at 4 h (Y2), mucoadhesive strength (Y3) and mucoadhesive 
time (Y4
 
) were selected as dependent variables. A statistical model, 
incorporating interactive and polynomial terms, was used to 
evaluate the response. 




-1 0 +1 
X1 17.5 mg (10 %) : HPC 35 mg (20 %) 52.5 mg (30%) 
X2 17.5 mg (10 %) : PEO WSR-1105 35 mg (20 %) 52.5 mg (30%) 
Dependent variables: Y1: in vitro drug release at 1 h, Y2: in vitro release drug 4 h, Y3: mucoadhesive strength (g), Y4
 
: mucoadhesion time (min) 
Table 2: Composition of factorial batches 
Ingredients Batches (Qty. in mg) 
F1 F2 F3 F4 F5 F6 F7 F8 F9 
Carvedilol solid dispersion 
equivalent to 6.25 mg carvedilol  
18.75 18.75 18.75 18.75 18.75 18.75 18.75 18.75 18.75 
HPC 17.5 35 52.5 17.5 35 52.5 17.5 35 52.5 
PEO WSR-1105 17.5 17.5 17.5 35 35 35 52.5 52.5 52.5 
Pearlitol 200 SD 103.25 85.75 68.25 85.75 68.25 50.75 68.25 50.75 33.25 
PVP K-30 10 10 10 10 10 10 10 10 10 
Aspartame 1 1 1 1 1 1 1 1 1 
Aerosil 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 
Magnesium stearate 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 
Average weight of tablets 175 175 175 175 175 175 175 175 175 
 
Evaluation of buccal tablets 
Tablet thickness and diameter 
Thickness and diameter of tablets were important for uniformity of 
tablet size. Thickness and diameter were measured using vernier 
calipers [17]. 
Hardness 
This test is used to check the hardness of a tablet, which may 
undergo chipping or breakage during storage, transportation and 
handling. In these five tablets will select at random and the hardness 
of each tablet will measure with Monsanto hardness tester. The 
hardness is usually measured in terms of kg/cm2
Friability 
 [17]. 
The friability test will carried out in Roche friabilator. Ten tablets 
weighed (W initial) initially and put in a rotating apparatus drum. Then, 
they are subjected to fall from 6 inches in height. After completion of 
100 rotations, the tablets again weighed (W final
 
). The percent loss in 
weight or friability (f) calculated by the formula given below [17]. 
% Drug content 
Uniformity of drug content was determined according to the following 
procedure. 10 tablets crushed in mortar pestle. Equivalent powder to 
dose 6.25 mg carvedilol was taken from the powder and dissolved in 
10 ml of methanol. The volume was made up to 100 ml with 
phosphate buffer pH 6.8 and sonicate for 20 min and then 1 ml was 
transferred to 10 ml volumetric flask and the volume was adjusted 
with phosphate buffer pH 6.8. The absorbance was measured on a UV-
Vis spectrophotometer at 240 nm. A concentration of carvedilol was 
calculated from a standard calibration curve of carvedilol [18]. 
Uniformity of weight 
This test is performed to maintain the uniformity of weight of each 
tablet, which should be in the prescribed range; this is done by 
sampling and weighing 20 tablets at random and average weight is 
calculated. The weight variation test was performed according to 
Indian Pharmacopeia [17]. 
In vitro drug release 
In vitro drug release was performed on buccal tablets using USP rotating 
paddle apparatus (Electrolab Dissolution Tester (USP) TDT-08L). The 
dissolution medium consisted of 500 ml of phosphate buffer pH 6.8. The 
experiment was performed at 37±0.5 °C, with a rotation speed of 50 
rpm. Buccal tablet was attached to the glass slide with instant adhesive 
(cyanoacrylate adhesive). The slide was placed at the bottom of the 
dissolution vessel. Samples (5 ml) were withdrawn at predetermined 
time intervals and the equivalent amount was replaced with fresh 
medium. The samples were filtered through Whatman filter (0.45 μm) 
paper and analyzed by UV spectrophotometer at 240 nm [18]. 
Ex vivo mucoadhesive strength 
A modified balance method was used for determining the ex vivo 
mucoadhesion strength. Porcine buccal mucosa was used as the 
model substrate and phosphate buffer pH 6.8 was used as the 
moistening fluid. Freshly excised porcine buccal mucosa was 
obtained from the local slaughterhouse used within three hours of 
slaughter. A preload of 50 gm was placed on the clamp for 5 min to 
establish an adhesive bond between the tablet and buccal mucosa. 
After completion of preload time, preload was removed from the 
clamp and water was added into the beaker from the burette at a 
constant rate. Mucoadhesive strength was measured in terms of 
weight in g of water required to detach the tablet from the buccal 
mucosa. The addition of water was stopped when tablet was 
detached from porcine buccal mucosa. The weight of water required 
to detach the tablet from buccal mucosa was noted as ex vivo 
mucoadhesive strength. Mucoadhesive strength was performed in 
triplicate and average mucoadhesive strength was determined [19]. 
Surface pH study 
The surface pH of the buccal tablet was determined in order to 
investigate the possibility of any side effects in vivo. As an acidic or 
alkaline pH may irritate the buccal mucosa, we sought to keep the 
surface pH as close to neutral as possible. A combined glass 
electrode was used for this purpose. The tablet was allowed to swell 
by keeping it in contact with 1 ml of phosphate buffer pH 6.8 for 2 h 
at room temperature. The pH was identified by bringing the 
electrode into contact with the tablet surface and allowing it to 
equilibrate for 1 min [11]. 
Patel et al. 
Int J App Pharm, Vol 12, Issue 4, 2020, 170-181 
172 
Ex vivo mucoadhesion time 
The ex vivo mucoadhesion time of mucoadhesive buccal tablets was 
determined using a modified USP dissolution apparatus. The 
dissolution medium was composed of 500 ml of phosphate buffer pH 
6.8 maintained at 37 °C. A segment porcine buccal mucosa each of 3 
cm length, was tied to the surface of glass slide, which was then 
vertically attached to the apparatus. The buccal tablet was hydrated 
using 15μl of pH 6.8 phosphate buffer on one side and a hydrated 
surface was brought into contact with the mucosal membrane for 30 
sec. The glass slide was vertically fixed to the apparatus and allowed 
to run in such way that the tablet completely immersed in the buffer 
solution at the lowest point and was out at the highest point. Tablet 
adhesion was monitored for 12 h. The time necessary for complete 
erosion or detachment of the carvedilol buccal tablet from the 
mucosal surface was recorded. The experiments were performed in 
triplicate (n = 3) and the mean of triplicate was determined [1]. 
Ex vivo drug permeability 
Ex vivo drug permeation study was carried out by using Franz 
diffusion apparatus. Porcine buccal mucosa was mounted on a 
diffusion cell between the donor and receptor compartment. The 
mucoadhesive tablet was fixed on the mucosal membrane. One 
milliliter phosphate buffer pH 6.8 in the donor compartment and 50 
ml of the same phosphate buffer in the receptor compartment was 
filled as dissolution fluid. The fluid was maintained at 37±0.5 ᵒC and 
stirred continuously at very low speed i.e. 50 RPM with the help of a 
magnetic stirrer. The external jacket was connected with a water 
bath so as to maintain the temperature in the Franz diffusion cell. 
Aliquots of 1 ml were collected at a pre-specified time interval for 8 
h, filtered through 0.45 µm membrane filter and the amount of drug 
was determined by measuring the absorbance of the aliquots at 240 
nm using UV–VIS spectrophotometer. Pre warmed (37±0.5 ᵒC) 
phosphate buffer was added to the diffusion cell after each 
withdrawal of the sample. The experiment was carried out in 
triplicate (n = 3) and the mean value was taken for the 
determination of ex vivo drug permeation [5]. 
In vitro release kinetic study 
The drug release data of buccal tablets were fitted to kinetics 
models, that is, zero order, first order, higuchi and Korsmeyer-
Peppas to find out drug release pattern and mechanisms [15]. 
 
RESULTS AND DISCUSSION 
Drug–excipients compatibility study by FTIR 
 
Fig. 1: IR spectra of carvedilol 
 
 
Fig. 2: IR spectra of the physical mixture (Carvedilol+Poloxamer 188+HPC+PEO) 
 
Table 3: IR spectra peaks 
S. No. Functional group Wave no (cm-1) 
1 C=C stretching 1590 
2  N-H stretching 3350 
3 C-H stretching 3050 
4 C-N stretching 1100 
5 O-H stretching 3200-3300 
 
From the IR studies, important function group IR bands of pure drug 
and physical mixture were identified. Characteristic IR bands of 
carvedilol includes the presence of peaks at 1590 cm-1 (C=C 
stretching),, 3350 cm-1 (N-H stretching), 3050 cm-1 (C-H stretching), 
1100 cm-1(C-N stretching) and 3200-3300 cm-1
 
(O-H stretching) 
which remained unaltered in IR spectrum of the physical mixture of 
drug and polymers. IR analysis revealed that there is no interaction 
between drug and polymers [14]. 
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Characterization of solid dispersion by differential scanning calorimetry (DSC) study 
 
Fig. 3: DSC study of carvedilol 
 
 
Fig. 4: DSC study of poloxamer 188 
 
 
Fig. 5: DSC study of carvedilol and poloxamer-188 
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Fig. 6: DSC study of carvedilol solid dispersion 
 
DSC analysis was employed to evaluate the phase of transformation 
during the formation of solid dispersions. DSC thermogram of 
carvedilol showed an endothermic peak at 118.73 °C, corresponding 
to its melting point. Poloxamer 188 showed an endothermic peak at 
58.77 °C. The DSC thermogram of the physical mixture and solid 
dispersion showed endothermic peaks corresponding to the melting 
point of poloxamer 188. The intensity of carvedilol peak is decreased 
in the physical mixture could be explained by a lower amount of 
carvedilol in physical mixtures and dissolving of carvedilol in melted 
carriers. The absence of carvedilol’s endothermic peak in case of 
solid dispersion suggests molecular dispersion of the drug in 
poloxamer 188. Thus, the crystalline drug could not be detected with 
DSC in these systems and converted in the amorphous state [20, 21]. 
Factorial design batches tablets evaluation parameters 
Prepared tablets of all batches were evaluated for weight variation, 
hardness, thickness, % drug content and friability. Results of all 
batches are shown in table 4. 
 
Table 4: Results of factorial design batches tablets evaluation 
Batch code Weight variation (mg) Hardness (kg/cm* 2) Thickness (mm)# % Drug content #  % Friability $ $ 
F1 174.2±2.40 5.54±0.18 1.98±0.02 101.82±0.92 0.34±0.10 
F2 175.5±1.82 5.82±0.25 2.02±0.05 101.63±1.23 0.32±0.15 
F3 175.4±1.43 5.78±0.17 2.04±0.03 102.82±2.21 0.28±0.05 
F4 175.8±2.12 6.21±.0.18 2.14±0.023 101.84±1.28 0.19±0.12 
F5 175.4±1.54 6.43±0.15 2.03±0.024 101.92±1.92 0.17±0.05 
F6 175.3±1.92 5.98±0.15 2.01±0.023 99.82±1.82 0.30±0.15 
F7 175.9±1.21 6.01±0.14 1.93±0.043 100.22±1.98 0.12±0.15 
F8 175.3±1.32 6.08±0.17 1.94±0.03 99.87±1.94 0.17±0.08 
F9 175.8±1.83 5.79±0.20 1.92±0.01 99.54±1.90 0.28±0.05 
*n=20, # n=5, $= 10. (mean±SD) 
 
The prepared tablets were smooth and white in color. Weight 
variation in case of all tablets was acceptable. The weight variation in 
case of all the tablets was within±2.5% of theoretical tablet weight. 
This falls well within the acceptance criteria. Hardness value of all the 
formulation was in the range of 5.54-6.43 kg/cm2
Ex vivo mucoadhesive strength, mucoadhesion time and surface pH 
. The prepared 
tablets showed in range thickness of 1.92-2.14 mm. Percentage of drug 
content for all formulations was found to be between 99.54% and 
102.82%. Friability in case of all the designed tablets was less than 1% 
indicating suitability of the method used for manufacturing the tablets. 
The ex vivo mucoadhesive strength and mucoadhesion time of the 
tablets were determined for all formulations using porcine buccal 
mucosa, which are shown in table 5. Ex vivo mucoadhesive strength 
was found between 11.82±0.82 g to 30.28±1.09 g. Highest 
Mucoadhesive strength was found in batch F9. Ex vivo mucoadhesion 
time was found between 220±1.2 min to 580±2.2 min. The 
maximum and minimum surface pH of the formulations found to be 
6.78±0.035 and 6.23±0.015, respectively. The surface pH was 
determined in order to investigate the possibility of any side effects, 
in the oral cavity as acidic or alkaline pH is bound to cause irritation 
to the buccal mucosa. The acceptable pH of saliva is in the range of 5 
to 7. So these formulations may not produce any mucosal irritation 
in buccal mucosa [16, 22]. The surface pH of all the formulations is 
shown in table 5. 
In vitro drug release 
The drug release of carvedilol buccal tablets was found between 
101.02±2.12 to 53.14±1.34. Batch F5 showed the drug release 
was 96.23±2.45 after 8 h. In vitro release study data indicate that 
duration of release of drugs is dependent on the percentage of 
selected polymer used in the formulations. An increase in the 
polymer concentration not only causes increase in the viscosity 
of the gel but also leads to formation of gel layer with a longer 
diffusion path. This leads to a decrease in the diffusion of the 
drug and therefore a reduction in the drug release rate [22-24]. 
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Table 5: Ex vivo mucoadhesive strength, time and surface pH 
Batch code Mucoadhesive strength (g) Ex vivo mucoadhesion time (min) Surface pH 
F1 11.82±0.82 220±1.2 6.23±0.015 
F2 15.28±0.85 300±1.4 6.28±0.017 
F3 16.44±0.92 440±2.3 6.34±0.015 
F4 16.72±0.79 240±1.5 6.54±0.030 
F5 18.20±1.44 420±2.6 6.75±0.015 
 F6 20.23±1.11 460±2.5 6.54±0.015 
 F7 24.23±1.09 470±2.5 6.57±0.005 
 F8 25.24±1.75 540±2.3 6.59±0.043 
 F9 30.28±1.09 580±2.2 6.78±0.035 
 *n = 3. (mean±SD) 
 
Table 6: In vitro drug release 
Time (h) % Cumulative release 
F1 F2 F3 F4 F5 F6 F7 F8 F9 
1 35.24±1.21 31.15±1.32 28.48±1.43 30.45±2.12 28.77±1.65 25.88±1.45 25.19±1.43 21.37±1.89 17.00±1.34 
2 51.52±1.67 46.24±2.56 42.42±1.56 43.82±1.32 47.54±2.56 35.65±2.67 36.43±2.12 32.2±1.56 26.22±1.32 
3 68.42±1.34 63.29±2.12 54.62±1.67 62.45±1.26 59.66±1.56 50.25±1.32 42.54±1.34 41.65±1.67 32.95±1.54 
4 81.4±2.12 75.5±1.34 64.78±2.12 69.24±1.52 70.52±1.32 61.45±1.34 52.65±1.52 49.52±1.72 39.69±1.32 
5 97.23±2.12 90.12±1.56 75.45±1.43 85.23±1.56 84.66±1.43 65.22±2.12 63.43±1.43 56.43± 44.71±1.32 
6 101.02±2.12 95.64±2.12 90.65±2.56 93.12±1.67 89.32±2.58 69.54±1.67 74.53±1.62 62.43±1.32 48.33±1.45 
7 - 100.21±1.2 95.34±1.34 98.12±1.39 94.4±1.56 71.45±1.45 78.64±2.45 65.34±2.12 52.45±1.67 
8 - - 98.54±2.52 101.45±1.69 96.23±2.45 72.07±1.59 80.28±1.92 69.42±1.67 53.14±1.34 
*Values are expressed as mean±SD (n=6) 
 
 
Fig. 7: In vitro drug release data of F1-F9 batches (n=6) 
 
Regression analysis for the effect of X1 (HPC) and X2 (PEO WSR-1105) on Y1
 
 (in vitro drug release at 1 h  
 
Fig. 8: Surface response plot of Y1 
DESIGN-EXPERT Plot
In Vitro drug relase at 1 h
X = A: HPC
Y = B: PEO WSR -1105
17. 4904  
21. 7429  
25. 9954  
30. 2479  















  17. 50
  26. 25
  35. 00
  43. 75
  52. 50
17. 50
26. 25  
35. 00  
43. 75  
52. 50  
  A :  H P C   
  B :  P E O  W S R  -1 1 0 5   
Patel et al. 
Int J App Pharm, Vol 12, Issue 4, 2020, 170-181 
176 
Table 7: Regression analysis for Y1
Regression statistics Y
 (in vitro drug release at 1 h) 
1 
R Square 0.9864 
Adjusted R square 0.9767 
Source 
Source Sum of squares P-value 
Model(Quadratic) 244.73 <0.0001 
X 63.51 1 <0.0001 
X 165.48 2 <0.0001 
X1X 0.51 2 0.3376 
X1 0.18 2 0.5593 
X2 11.43 2 0.0017 
 
Full model equation 
Y1 = 28.67-3.25X1-5.25X2–0.36X1X2–0.26X12-2.06 X2 2
Reduced model equation on the basis of p value 
 …… (1) 
Y1 = 28.67-3.25X1-5.25X2–-2.06 X2 2
Higher values of correlation coefficients for drug release at 1 h 
indicate a good fit. The polynomial equations can be used to draw 
conclusions after considering the magnitude of the coefficient and 
the mathematical sign it carries. Here p-Value for X
 …… (2) 
1 and X2 was less 
than 0.05. So HPC and PEO WSR-1105 both had a significant effect 
on % cumulative drug release. HPC and PEO had a negative effect on 
% cumulative release so it was concluded that % drug release 
decreased with an increase the concentration of HPC and PEO WSR-
1105. The coefficients b1, b2 and b2 2 were found to be significant at 
p is less than 0.05 and thus, were retained in the reduced model 
equation [17, 25]. Here b2 value is more negative than b1, 
 
which 
indicated that PEO had more release retardant effect compare to the 
HPC at 1 h. 
Regression analysis for the effect of X1 (HPC) and X2 (PEO WSR-1105) on Y2 
 
(in vitro drug release at 4 h  
 
Fig. 9: Surface response plot of Y
 
2 
Table 8: Regression analysis for Y2  
Regression statistics Y
(in vitro drug release at 4 h) 
2 
R Square 0.9877 
Adjusted R square 0.9788 
Source 
Source Sum of squares P-value 
Model (Quadratic)  1525.08 <0.0001 
X 232.75 1 <0.0001 
X 1061.87 2 <0.0001 
X1X 3.35 2 0.3040 
X1 34.76 2 0.0092 
X2 112.15 2 0.0004 
 
DESIGN-EXPERT Plot
In vitro drug releaase at 4 h
X = A: HPC
Y = B: PEO WSR -1105
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Full model equation 
Y2 = 69.32-6.23X1-13.30X2+0.91X1X2–3.54X12-6.37X2 2
Reduced Model Equation on the basis of p value 
 ….. (3) 
Y2 = 69.32-6.23X1-13.30X2–3.54X12-6.37X2 2
Higher values of correlation coefficients for drug release at 4 h 
indicate a good fit. The polynomial equations can be used to draw 
conclusions after considering the magnitude of the coefficient and 
the mathematical sign it carries. Here p-Value for X
 …… (4) 
1 and X2 was less 
than 0.05. So HPC and PEO WSR-1105 both had a significant effect 
on % cumulative drug release. HPC and PEO WSR-1105 had a 
negative effect on % cumulative release so it was concluded that % 
drug release decreased with an increase the concentration of HPC 
and PEO WSR-1105. The coefficients b1, b2, b12and b22 were found 
to be significant at p is less than 0.05 and thus, were retained in the 
reduced model equation [17, 25]. Here b2 value is more negative 
than b1, 
 
which indicated that PEO had more release retardant effect 
compare to the HPC at 4 h. 
Regression analysis for the effect of X1 (HPC) and X2 (PEO WSR-1105) on Y3 
 
(mucoadhesive strength) 
Fig. 10: Surface response plot of Y
 
3 




R Square 0.9851 
Adjusted R square 0.9744 
Source 
Source Sum of squares P-value 
Model (Quadratic) 271.79 <0.0001 
X 33.51 1  0.0001 
X 220.46 2 <0.0001 
X1X 0.51 2 0.3826 
X1 0.27 2 0.5205 
X2 13.09 2 0.0022 
 
Full model equation 
Y3 = 18.19+2.36X1+6.06X2+0.36X1X2+0.31X12+2.18X2 2
Reduced Model Equation on the basis of p value 
 (5) 
Y3 = 18.19+2.36X1+6.06X2+2.18X22
Higher values of correlation coefficients for mucoadhesive strength 
indicate a good fit. Here p-Value for X
(6) 
1 and X2 was less than 0.05 so 
HPC and PEO WSR-1105 both had a significant effect on 
mucoadhesive strength (Y3). HPC and PEO WSR-1105 had a positive 
effect on mucoadhesive strength. This may be due to fact that 
positive charges on the surface of HPC and PEO WSR-1105 could 
give rise to strong electrostatic interaction with mucous or 
negatively charged mucous membranes. In equation (5) show that 
PEO WSR-1105 (X2
 
) had higher positive value than HPC (X1). So, it 
was concluded that PEO WSR-1105 has more superior 
mucoadhesive property compare to HPC. This can be attributed due 
to higher flexibility of polymeric chains of PEO resulting in better 
interaction with mucins [16, 23]. 




R Square 0.8941 
Adjusted R square 0.8730 
Source 
Source Sum of squares P-value 
Model (Linear) 1166000 <0.0001 
X 50416.67 1 0.0001 
X 66150 2 <0.0001 
DESIGN-EXPERT Plot
Mucoadhesive strength
X = A: HPC
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Regression analysis for the effect of X1 (HPC) and X2 (PEO WSR-1105) on Y4 
 
(mucoadhesion time) 
Fig. 11: Surface response plot of Y
 
4 
Full model equation 
Y4 = 411.54+91.67X1+105.00X2 ……. 
Here p-Value for X
(7) 
1 and X2 was less than 0.05 so HPC and PEO WSR-
1105 both had a significant effect on Mucoadhesive time (Y4). Above 
equation (7) showed that HPC and PEO WSR-1105 had a positive 
effect on mucoadhesive time but PEO WSR-1105 (X2
 
) has a higher 
positive value than HPC (X1) so it was concluded that mucoadhesive 
time increased with an increase the concentration of PEO WSR-1105 
compare to HPC. 
Validation of design model by checkpoint batches 
 
Fig. 12: Overlay plot of response variables 
 
Preparation of checkpoint batches from overlay plot 
Checkpoint batch C1 and C2 were selected from the overlay plot of 
responses. The amount of HPC and PEO WSR-1105 and according to 
their amounts, the predicted responses were given in the Overlay 
plot flag or in the solution of overlay data. From that, any two 
batches C1 and C2 were selected for the verification of the model 
[17].
 
Table 11: Formulation for checkpoint batch 
Ingredients Quantity taken (mg) 
C C1 2 
Carvedilol solid dispersion equivalent to 6.25 mg carvedilol 18.75 18.75 
HPC 20.96 42.23 
PEO WSR-1105 48.45 27.87 
PVP K30 10 10 
 Aspartame 1 1 
Pearlitol 200 SD 68.84 68.15 
 Magnesium Stearate 3.5 3.5 
Aerosil 3.5 3.5 
Total (mg) 175 175 
DESIGN-EXPERT Plot
Mucoadhesion time
X = A: HPC
Y = B: PEO WSR -1105
214. 872  
313. 205  
411. 538  
509. 872  
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1 7 . 5 0 2 6 . 2 5 3 5 . 0 0 4 3 . 7 5 5 2 . 5 0
1 7 . 5 0
2 6 . 2 5
3 5 . 0 0
4 3 . 7 5
5 2 . 5 0
I n V it ro drug relas e at  1 h:  25
I n v it ro drug releaas e at  4 h:  65
I n v it ro drug releaas e at  4 h:  75
M uc oadhes iv e s t rengt h:  15
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5
In  V i tr o 26 .083
In  vi tr o  57 .4902
M uc oad 22 .218
M uc oad 418 .686
X 20 .96
Y 48 .45
In  V i tr o 29 .1394
In  vi tr o  70 .3497
M uc oad 17 .0513
M uc oad 406 .654
X 42 .23
Y 27 .87
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Table 12: Validation of model by comparing predicted response to actual response 
Predicted response and the actual response of checkpoint batch 
Evaluation parameters Batch C1 Batch C2 
Predicted value Actual value % Error Predicted value Actual value % Error 
% drug release at 1 h 26.083% 27.18% 4.20% 29.1394% 28.75% 1.33% 
% drug release at 4 h 57.49% 58.89% 2.43% 70.349% 69.10% 1.77 
Mucoadhesive strength 22.218 gm 21.5 gm 4.59% 17.051 gm 16.4 gm 3.81% 
Mucoadhesion time 418.686 min 422 min 0.79% 406.654 min 400 min 1.63% 
 
Actual response of C1 and C2 batch was measured and compared with 
the predicted response of checkpoint batch. % error was found to be less 
than 5 of all the responses. Hence, this model was valid and an optimized 
batch can be selected from the overlay plot of this model. 
 
Optimized batch from overlay plot 
 
Fig. 13: Optimized batch from overlay plot 
 
The contour plots are evolved for each response, which divides the 
plot surface into a desirable and not desirable zone. A contour for 
each response is then superimposed to locate the area where the 
targets for the all response are achieved. Here in above fig. 13 shows 
the yellow area was the optimized area and Batch F5 was fall in the 
yellow region [15]. 
Ex vivo permeation study 
Optimized batch was selected for the ex vivo permeation study. The 
buccal mucosa of pigs resembles that of humans more closely than 
any other animal in terms of structure and composition and 
therefore, porcine buccal mucosa was selected for drug permeation 
studies. The drug permeation slow and 83.24 % of carvedilol 
permeated through buccal mucosa after 8 h [26]. The result of ex 
vivo permeation study is shown in table 13. 
In vitro release kinetic study 
Dissolution profiles were fitted to various model and release data 
were analyzed on the basis of Koresmeyer-Peppas, zero order, first 
order and higuchi models. The best fit model was selected on the 
basis of R2
  
 values. Thus, it may be concluded that from the above 
data Korsmeyer-Peppas model was followed by formulation n value 
between 0.5-0.85, which showed that anomalous (non-Fickian) 
diffusion [27]. The in vitro release kinetic data is shown in table 14. 
Table 13: Ex vivo permeation study 
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I n V it ro drug relas e at  1 h:  25
I n v it ro drug releaas e at  4 h:  65
I n v it ro drug releaas e at  4 h:  75
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M uc oadhes iv e s t rengt h:  21
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5
In  V i tr o 28 .6355
In  vi tr o  69 .2135
M uc oad 18 .2422
M uc oad 411 .988
X 35 .00
Y 35 .00
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Table 14: In vitro release kinetic study 
Batch code Zero order First order Higuchi Korsmeyer-peppas  
R R2 R2 R2 n 2 
F1 0.9497 0.9380 0.9668 0.9912 0.611913 
F2 0.9432 0.9540 0.9655 0.9872 0.628234 
F3 0.9542 0.8064 0.9618 0.9899 0.621277 
F4 0.9338 0.9532 0.9705 0.9843 0.607026 
F5 0.9543 0.9830 0.9747 0.9932 0.592808 
F6 0.8629 0.9051 0.9470 0.9492 0.526823 
F7 0.9488 0.9692 0.9599 0.9826 0.589123 
F8 0.9287 0.9564 0.9876 0.9939 0.576665 
F9 0.9158 0.8715 0.9872 0.9895 0.562149 
 
CONCLUSION 
The mucoadhesive buccal tablets of carvedilol were successfully 
prepared by direct compression techniques using polymer like HPC 
and PEO WSR-1105 to avoid the first-pass metabolism. Solubility of 
carvedilol was improved by solid dispersion technique using 
poloxamer 188. From all Parameters and experimental design 
evaluation, it was concluded that the drug release rate decreased 
with an increase the concentration of HPC and PEO WSR-1105. Here 
PEO had a more significant effect in mucoadhesive property of tablet 
compare to HPC. So, mucoadhesion time and mucoadhesive strength 
of formulation was increased with increasing the concentration of 
PEO WSR-1105. The in vitro release kinetics revealed Korsmeyer-
Peppas model is followed and drug release is by anomalous 
diffusion. 
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